
    
      Subjects who have been identified to have severe asthma with ABPA will be consented and
      enrolled in the study to receive benralizumab injections administered every 4 weeks for the
      first 3 injections with an additional injection eight weeks to follow for a total of 16 weeks
      active treatment with a follow-up/termination visit eight weeks from the last injection. The
      termination visit will occur week 24 for subjects who complete the study treatment. Subjects
      who receive the first dose of benralizumab but withdraw from the study or terminate study
      treatment for any reason should complete all the procedures outlined for the termination
      visit.
    
  